These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 18488711)
1. Epoxyquinol B shows antiangiogenic and antitumor effects by inhibiting VEGFR2, EGFR, FGFR, and PDGFR. Kamiyama H; Kakeya H; Usui T; Nishikawa K; Shoji M; Hayashi Y; Osada H Oncol Res; 2008; 17(1):11-21. PubMed ID: 18488711 [TBL] [Abstract][Full Text] [Related]
2. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo. Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074 [TBL] [Abstract][Full Text] [Related]
3. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925 [TBL] [Abstract][Full Text] [Related]
4. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Taeger J; Moser C; Hellerbrand C; Mycielska ME; Glockzin G; Schlitt HJ; Geissler EK; Stoeltzing O; Lang SA Mol Cancer Ther; 2011 Nov; 10(11):2157-67. PubMed ID: 21885862 [TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling. Huang SW; Lien JC; Kuo SC; Huang TF Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611 [TBL] [Abstract][Full Text] [Related]
6. A novel synthetic small molecule YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling. Liu Y; He Y; Yang F; Cong X; Wang J; Peng S; Gao D; Wang W; Lan L; Ying X; Liu M; Chen Y; Yi Z Sci China Life Sci; 2017 Feb; 60(2):202-214. PubMed ID: 28194552 [TBL] [Abstract][Full Text] [Related]
7. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo. Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720 [TBL] [Abstract][Full Text] [Related]
8. YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models. Xia Y; Song X; Li D; Ye T; Xu Y; Lin H; Meng N; Li G; Deng S; Zhang S; Liu L; Zhu Y; Zeng J; Lei Q; Pan Y; Wei Y; Zhao Y; Yu L Sci Rep; 2014 Aug; 4():6031. PubMed ID: 25112436 [TBL] [Abstract][Full Text] [Related]
9. Oleanolic Acid Inhibits Colorectal Cancer Angiogenesis by Blocking the VEGFR2 Signaling Pathway. Niu G; Sun L; Pei Y; Wang D Anticancer Agents Med Chem; 2018; 18(4):583-590. PubMed ID: 29065844 [TBL] [Abstract][Full Text] [Related]
10. Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis. Li T; Liu X; Shen Q; Yang W; Huo Z; Liu Q; Jiao H; Chen J Oncotarget; 2016 May; 7(18):26580-92. PubMed ID: 27058891 [TBL] [Abstract][Full Text] [Related]
11. Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor growth, and metastasis through PI3K/AKT and MAPK/ERK1/2 pathway. Sadremomtaz A; Mansouri K; Alemzadeh G; Safa M; Rastaghi AE; Asghari SM Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2688-2700. PubMed ID: 30251659 [TBL] [Abstract][Full Text] [Related]
12. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466 [TBL] [Abstract][Full Text] [Related]
13. Selenadiazole Derivatives Inhibit Angiogenesis-Mediated Human Breast Tumor Growth by Suppressing the VEGFR2-Mediated ERK and AKT Signaling Pathways. Lai H; Fu X; Sang C; Hou L; Feng P; Li X; Chen T Chem Asian J; 2018 Jun; 13(11):1447-1457. PubMed ID: 29575811 [TBL] [Abstract][Full Text] [Related]
14. Cryptotanshinone inhibits VEGF-induced angiogenesis by targeting the VEGFR2 signaling pathway. Xu X; Wu L; Zhou X; Zhou N; Zhuang Q; Yang J; Dai J; Wang H; Chen S; Mao W Microvasc Res; 2017 May; 111():25-31. PubMed ID: 28040437 [TBL] [Abstract][Full Text] [Related]
15. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. McCarty MF; Wey J; Stoeltzing O; Liu W; Fan F; Bucana C; Mansfield PF; Ryan AJ; Ellis LM Mol Cancer Ther; 2004 Sep; 3(9):1041-8. PubMed ID: 15367698 [TBL] [Abstract][Full Text] [Related]
16. Novel angiogenesis inhibitory activity in cinnamon extract blocks VEGFR2 kinase and downstream signaling. Lu J; Zhang K; Nam S; Anderson RA; Jove R; Wen W Carcinogenesis; 2010 Mar; 31(3):481-8. PubMed ID: 19969552 [TBL] [Abstract][Full Text] [Related]
17. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Hilberg F; Roth GJ; Krssak M; Kautschitsch S; Sommergruber W; Tontsch-Grunt U; Garin-Chesa P; Bader G; Zoephel A; Quant J; Heckel A; Rettig WJ Cancer Res; 2008 Jun; 68(12):4774-82. PubMed ID: 18559524 [TBL] [Abstract][Full Text] [Related]
18. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways. Li X; Wang X; Ye H; Peng A; Chen L Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678 [TBL] [Abstract][Full Text] [Related]
19. Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathway. He L; Wu Y; Lin L; Wang J; Wu Y; Chen Y; Yi Z; Liu M; Pang X Cancer Sci; 2011 Jan; 102(1):219-25. PubMed ID: 21087351 [TBL] [Abstract][Full Text] [Related]
20. Rhamnazin, a novel inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy. Yu Y; Cai W; Pei CG; Shao Y Biochem Biophys Res Commun; 2015 Mar; 458(4):913-9. PubMed ID: 25704088 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]